Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes

Acta Diabetologica

Volumn 50, Issue 4, 2013, Pages 537-543

  Faghihimani, Elham ^a   Aminorroaya, Ashraf ^a   Rezvanian, Hassan ^a   Adibi, Peyman ^b   Ismail Beigi, Faramarz ^c   Amini, Masoud ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycemic control; Salsalate; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SALSALATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; LIPID ANALYSIS; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; SIDE EFFECT; TINNITUS; TREATMENT DURATION; VOMITING; WEIGHT CHANGE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; SALICYLATES;

EID: 84884902312     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0329-2     Document Type: Article

References (30)

1. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes 21:1414-1431 (Pubitemid 28405191)
2. zachary t. bloomgarden (2003) Inflammation and insulin resistance. Diabetes Care 26(6):1922-1926
3. Duncan BB, Schmidt MI (2006) The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther 8:7-17
4. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R (2002) Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105:2019-2023 (Pubitemid 34465262)
5. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle aged men: results from the MONICA Ausburg cohort study. Arch Intern Med 163:93-99 (Pubitemid 36091606)
6. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021 (Pubitemid 41071061)
7. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2002) Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102:42-47
8. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G (2003) Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88:5321-5326 (Pubitemid 37452734)
9. Duncan BB et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805 (Pubitemid 36792473)
10. Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48:1038-1050 (Pubitemid 40909636)
11. Shoelson SE, Lee J, Yuan M (2003) Inflammation and the IKKβ/IκB/NF-κB axis in obesity and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27(Suppl. 3):S49-S52 (Pubitemid 38019189)
12. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793-1801
13. Cai D et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKKβ and NF-κB. Nat Med 11:183-190 (Pubitemid 40321354)
14. Tilg H, Moschen AR (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14(3-4):222-231 (Pubitemid 351481853)
15. Rumore MM, Kim KS (2010) Potential role of salicylates in type 2 diabetes. Ann Pharmacol 44:1207-1221
16. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia 52:385-393
17. Fleischman A, Shoelson SE, Bernier R, Goldfine AB (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289-294 (Pubitemid 351213338)
18. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IkkB. Science 293:1673-1677 (Pubitemid 32807849)
19. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI (2002) Mechanism by which highdose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326 (Pubitemid 34546896)
20. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396:77-80 (Pubitemid 28520452)
21. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK (1999) Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes. J Immunol 163:5608-5616
22. Anonymous (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62, 8 pp
23. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, for the TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team (2010) The effects of Salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346-357
24. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137 (Pubitemid 34438360)
25. Hostamisligil GS et al (1996) IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271:665-668
26. Vozarova B et al (2002) High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:455-461 (Pubitemid 34764803)
27. Haiyan Xu, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Hong Chen J (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Clin Invest 112:1821-1830 (Pubitemid 38063705)
28. Fernandez-Real J-M, Lopez-Berejo A et al (2008) Salicylates increase insulin secretion in healthy obese subjects. J Clin Endocrinol Met 93:2523-2530 (Pubitemid 352008516)
29. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhäusl WK (1985) Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 28:671-676 (Pubitemid 16226405)
30. Wallace TA, Levy JC, Mathews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495 (Pubitemid 38680001)